FierceBiotech 2026年4月1日 KBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo Nordisk
FierceBiotech 2026年3月31日 Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
FierceBiotech 2026年3月31日 Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play
FierceBiotech 2026年3月31日 Obesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic
FierceBiotech 2026年3月31日 AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan
FierceBiotech 2026年3月31日 Lipella files for bankruptcy, ending dream of developing mouth inflammation drug
FierceBiotech 2026年3月30日 Astellas axes early Sjögren’s trial in latest setback for autoimmune disease community
FierceBiotech 2026年3月30日 Viridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincing
FierceBiotech 2026年3月30日 Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
FierceBiotech 2026年3月30日 Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals
FierceBiotech 2026年3月30日 Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025